



ateco™

INFORMED BY EOS

# Q1 2026 FINANCIAL RESULTS

PAT MILES, CHAIRMAN & CEO | TODD KONING, EVP & CFO | MAY 5, 2026

# FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth, adjusted EBITDA, profitability, free cash flow, financial outlook and commitments; planned product launches, timelines, introductions, regulatory submissions or clearances; expansion of international markets; increases in U.S. market share and procedural volume, the ability to drive surgeon adoption, gain hospital access and create clinical distinction; the development and monetization of informatics platforms; the ability to transform the sales channel; and the Company's ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing and commercializing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating and long-range plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; competitive pressures and market dynamics; and the Company's ability to meet its financial obligations and achieve expected financial outcomes. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the U.S. Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

# INDUSTRY- LEADING PROFITABLE GROWTH

Q1 2026 HIGHLIGHTS

**\$192M**  
Total Revenue

**17%**  
Surgical Revenue  
Growth

**21%**  
Case Volume  
Growth

**23%**  
Net New Surgeon  
Growth

**\$14M**  
EOS Revenue

**\$21M**  
Adjusted EBITDA

**(\$11M)**  
Free Cash Use

# Q1 REVENUE PERFORMANCE

GROWTH DRIVEN BY SURGICAL VOLUME

	Q1 2026	YOY\$	YOY%
Surgical Revenue	\$178M	\$26M	17%
EOS Revenue	\$14M	(\$3M)	(18%)
<b>TOTAL REVENUE</b>	<b>\$192M</b>	<b>\$23M</b>	<b>14%</b>

**\$26M**

Surgical Revenue  
YoY \$ Growth


- 21% surgical volume growth
- Revenue per case down 3% year over year
  - U.S. surgical revenue per case down 2%
  - 130 bps headwind from OUS surgical case mix

# Q1 2026 NON-GAAP P&L HIGHLIGHTS

DISCIPLINED EXECUTION DRIVING PROFITABILITY

	Q1 2026	YOY
<b>TOTAL REVENUE</b>	<b>\$192M</b>	<b>14%</b>
Gross Margin %	71.6%	+120 bps
R&D %	7.1%	(50) bps
SG&A %	61.6%	(420) bps
Total Operating Expense %	68.7%	(480) bps
<b>OP PROFIT MARGIN %</b>	<b>2.9%</b>	<b>600 bps</b>

<b>ADJUSTED EBITDA \$</b>	<b>\$21M</b>	<b>97%</b>
% of Sales	10.8%	+460 bps



- Gross margin improvements driven by asset efficiency and product mix
- Overall operating expenses grew 6% YoY
- Adj. EBITDA grew 2x YoY; drop through of 45% YoY

# Q1 BALANCE SHEET

IMPROVING CASH FLOW AND SOLID BALANCE SHEET

BALANCE SHEET	Q1 2026
Cash	\$140M
Available Borrowing <sup>1</sup>	\$60M
<b>CASH + AVAILABLE CASH</b>	<b>\$200M</b>

CASH FLOW	Q1 2026
Operating Cash Flow <sup>2</sup>	\$22M
Inventory and PP&E	(\$33M)
<b>FREE CASH FLOW / (USE)<sup>3</sup></b>	<b>(\$11M)</b>

FCF at the favorable end of the (\$10M) to (\$15M) range

Trailing twelve-month FCF improved to +\$7M

# PROFORMA BALANCE SHEET

SAVING \$35 MILLION IN INTEREST EXPENSE OVER THE LIFE OF THE LOAN

## NEW TERM LOAN & REVOLVING CREDIT FACILITY

- ✓ Anchored by JP Morgan and TD Cowen
- ✓ Consolidates two legacy facilities into one
- ✓ Saves \$6M+ in interest annually
- ✓ Extends maturity to 2031

OLD LOANS	CAPACITY	MATURITY	RATE
-----------	----------	----------	------

Braidwell Term	\$200M	Jan '28	SOFR + 575
----------------	--------	---------	------------

Midcap ABL	\$75M	Sept '27	SOFR + 350
------------	-------	----------	------------



NEW LOAN	CAPACITY	MATURITY	RATE
----------	----------	----------	------

TLA & RCF	\$300M	May '31	SOFR + 275
-----------	--------	---------	------------

# 2026 REVENUE OUTLOOK

ADOPTION OF OUR UNIQUE PROCEDURAL APPROACH FUELS DURABLE REVENUE GROWTH

**\$882M**

Total Revenue

	FY'26E	YOY
Surgical Revenue	\$805M	<b>17%</b>
EOS Revenue	\$77M	0%
<b>TOTAL REVENUE</b>	<b>\$882M</b>	<b>15%</b>

**\$118M**

YoY Topline Growth

# 2026 FINANCIAL OUTLOOK

## GROWTH LEADERSHIP

**\$882M**

Total revenue;  
15% growth

## POWERFUL LEVERAGE

**\$134M**

Adjusted EBITDA;  
15% margin

## FREE CASH FLOW

**\$20M**

Investing in growth and  
generating cash

COMMITTED TO CONTINUING INDUSTRY-LEADING PROFITABLE GROWTH & INNOVATION

# OUR STRATEGY REMAINS STEADFAST

NO CHANGE TO THE FUNDAMENTALS OF OUR LONG-TERM GROWTH ALGORITHM

**1**

## CREATE CLINICAL DISTINCTION

Architect unparalleled procedural solutions that improve patient outcomes

**2**

## COMPEL SURGEON ADOPTION

Earn loyalty through differentiated training, technology, and clinical value


**3**

## EXPAND, ELEVATE & ENABLE SALES FORCE

Build a high-performing, aligned sales force designed to scale and win

# PROCEDURAL INNOVATION CONTINUES

NEW PRODUCTS DRIVING CONVOYED SALES, REINFORCING GROWTH DURABILITY



PCF

ACDF

POSTERIOR FIXATION

PLIF

LTP™


PTP™

TLIF


ALIF

# LATERAL CONFIDENCE CREATION EARNS SURGEON TRUST...


LATERAL DISTINCTION  
AND UNIQUE APPROACH TO  
PROCEDURAL SOLUTIONS



SURGEON USERS



SURGEON UTILIZATION




...AND EXPANDS UTILIZATION OF  
OUR ENTIRE PROCEDURAL PORTFOLIO ACROSS  
**CERVICAL | ANTERIOR | POSTERIOR**

# EOS: FROM ACCESS TO ADVANTAGE

CONVERTING ACCESS INTO HARDWARE PULL-THROUGH & LONG-TERM DATA ADVANTAGE

## 1. ACCESS

Entryway into leading, most prestigious institutions and KOL surgeons. Establishes ATEC rep presence in high-value strategic accounts



## 2. CLINIC INTEGRATION

Embedded beyond the O.R. into pre- and post-op clinical workflow, becoming standard practice for entire care team




## 3. EOS INSIGHT® PLAN

Data-driven, patient-specific plan aligns ATEC rep with procedural needs, enabling curated delivery of inventory




## 4. PATIENT-SPECIFIC RODS

Rods make ATEC rep integral to case execution, locking out competition and expanding hardware pull-through




## 5. COMPOUNDING DATA = LONG-TERM MOAT

Growing volume of structured imaging + longitudinal outcomes data enables continuous learning and informs future AI capabilities



30% AVERAGE REVENUE GROWTH ACROSS ESTABLISHED ATEC USERS AFTER EOS INSIGHT® ADOPTION



# EOS INSIGHT® GAINING MOMENTUM

SEEING TRACTION OF CLINICAL ADOPTION, BOLSTERED BY RELENTLESS PLATFORM ADVANCEMENT




**ODHA 3D PARAMETER**  
Proprietary quantitative measure of spinal alignment in 3D, derived from advanced EOS® imaging

**PATIENT-SPECIFIC PELVIS**  
Enables personalized alignment targets based on true pelvic morphology, augmenting pre-operative planning and intraoperative execution



MORE THAN JUST  
THE MOST COVETED IMAGING  
**A STRUCTURED DATA ADVANTAGE**  
A PROPRIETARY, ALGORITHMIC WAY  
TO PROCESS DATA



**RECIPROCAL CHANGE PREDICTION**  
Proprietary algorithm to anticipate how a specific patient's body will adapt and compensate after surgery, improving alignment accuracy and reducing risk of revision

# STRONG EARLY CLINICAL EXPERIENCE WITH VALENCE®


SURGEON FEEDBACK SIGNALS WINS ACROSS  
PROCEDURAL INTEGRATION & WORKFLOW EFFICIENCY





# ADVANCING PRESENCE AND INFLUENCE IN JAPAN

EARLY EXPERIENCE POSITIVE, WITH PTP™ SERVING AS KEY GROWTH LEVER FOR EXPANSION





**ATEC IS  
UNIQUELY  
POSITIONED**

**100% SPINE FOCUS**

COMPELLING SURGEON ADOPTION THROUGH CLINICAL DISTINCTION

**LEADING & ADVANCING LATERAL**

EARNING SHARE, DRIVING ADOPTION WITH VALENCE®

**DEFORMITY LEADERSHIP & EOS INSIGHT®**

PROCEDURAL GROWTH ENGINE, POISED FOR A PTP™-LIKE RUN

**INFRASTRUCTURE BUILT FOR LONG RUN**

FOUNDATIONAL INVESTMENTS ENABLE SCALE AND LONGEVITY

**DURABLE & PROFITABLE SALES GROWTH**

INFLECTED TO PROFITABILITY AND CASH FLOW

atec™

INFORMED BY EOS

THE PREFERRED  
DESTINATION IN SPINE.





atec™

INFORMED BY EOS

# APPENDIX

# SUPPLEMENTAL FINANCIAL INFORMATION



## HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$'000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Revenue from products and services	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155	\$ 192,108
Cost of sales	41,126	42,979	47,990	55,205	187,300	53,184	56,443	59,203	63,437	232,267	55,632
<b>Gross profit</b>	<b>97,351</b>	<b>102,594</b>	<b>102,729</b>	<b>121,588</b>	<b>424,262</b>	<b>115,996</b>	<b>129,101</b>	<b>137,300</b>	<b>149,491</b>	<b>531,888</b>	<b>136,476</b>
<b>Operating expenses:</b>											
Research and development	18,012	19,105	20,357	23,244	80,718	16,582	18,276	18,679	22,281	76,268	17,560
Sales, general and administrative	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526	137,057
Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
Amortization of acquired intangibles	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915
Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
Gain on Settlement											
<b>Total operating expenses</b>	<b>140,692</b>	<b>137,901</b>	<b>136,432</b>	<b>145,406</b>	<b>560,431</b>	<b>160,287</b>	<b>142,186</b>	<b>153,233</b>	<b>158,310</b>	<b>614,016</b>	<b>159,057</b>
<b>Operating Loss</b>	<b>(43,341)</b>	<b>(35,307)</b>	<b>(33,703)</b>	<b>(23,818)</b>	<b>(136,169)</b>	<b>(44,291)</b>	<b>(13,085)</b>	<b>(15,933)</b>	<b>(8,819)</b>	<b>(82,128)</b>	<b>(22,581)</b>
<b>Other expense, net:</b>											
Cash interest expense, net	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)	(5,312)	(5,184)	(21,141)	(4,953)
Noncash interest expense, net	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)	(7,566)	(7,710)	(24,781)	(6,768)
Loss on debt extinguishment	-	-	-	-	-	(17,576)	-	-	-	(17,576)	-
Gain on derivative liability	-	-	-	-	-	17,400	(16,780)	-	-	620	-
Other (expense) income, net	118	156	623	(1,922)	(1,025)	337	993	307	(34)	1,603	446
<b>Total other expense, net</b>	<b>(5,223)</b>	<b>(5,659)</b>	<b>(5,949)</b>	<b>(9,073)</b>	<b>(25,904)</b>	<b>(7,680)</b>	<b>(28,096)</b>	<b>(12,571)</b>	<b>(12,928)</b>	<b>(61,275)</b>	<b>(11,275)</b>
<b>Net loss before taxes</b>	<b>(48,564)</b>	<b>(40,966)</b>	<b>(39,652)</b>	<b>(32,891)</b>	<b>(162,073)</b>	<b>(51,971)</b>	<b>(41,181)</b>	<b>(28,504)</b>	<b>(21,747)</b>	<b>(143,403)</b>	<b>(33,856)</b>
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50
<b>Net loss, GAAP</b>	<b>\$ (48,495)</b>	<b>\$ (40,680)</b>	<b>\$ (39,616)</b>	<b>\$ (33,332)</b>	<b>\$ (162,123)</b>	<b>\$ (51,907)</b>	<b>\$ (41,144)</b>	<b>\$ (28,578)</b>	<b>\$ (21,729)</b>	<b>\$ (143,358)</b>	<b>\$ (33,906)</b>
<b>Net loss per share, GAAP</b>	<b>\$ (0.34)</b>	<b>\$ (0.29)</b>	<b>\$ (0.28)</b>	<b>\$ (0.23)</b>	<b>\$ (1.13)</b>	<b>\$ (0.35)</b>	<b>\$ (0.27)</b>	<b>\$ (0.19)</b>	<b>\$ (0.14)</b>	<b>\$ (0.96)</b>	<b>\$ (0.22)</b>
<b>Weighted average shares outstanding, basic and diluted</b>	<b>140,980</b>	<b>142,687</b>	<b>143,492</b>	<b>144,583</b>	<b>142,946</b>	<b>146,732</b>	<b>149,907</b>	<b>151,401</b>	<b>152,106</b>	<b>150,064</b>	<b>154,051</b>

# SUPPLEMENTAL FINANCIAL INFORMATION



## NON-GAAP RECONCILIATION - CONSOLIDATED (\$000's)

NON-GAAP GROSS PROFIT & GROSS MARGIN	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
<b>Gross Profit, GAAP</b>	\$ 97,351	\$ 102,594	\$ 102,729	\$ 121,588	\$ 424,262	\$ 115,996	\$ 129,101	\$ 137,300	\$ 149,491	\$ 531,888	\$ 136,476
+ Amortization of acquired intangible assets	307	307	308	(814)	108	50	64	65	66	245	66
+ Stock-based compensation	483	554	1,439	2,485	4,961	3,043	553	414	519	4,529	970
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-
<b>Non-GAAP Gross Profit</b>	<b>\$ 98,141</b>	<b>\$ 103,652</b>	<b>\$ 104,476</b>	<b>\$ 123,259</b>	<b>\$ 429,528</b>	<b>\$ 119,089</b>	<b>\$ 129,718</b>	<b>\$ 137,779</b>	<b>\$ 150,076</b>	<b>\$ 536,662</b>	<b>\$ 137,512</b>
<b>Gross Margin, GAAP</b>	<b>70.3%</b>	<b>70.5%</b>	<b>68.2%</b>	<b>68.8%</b>	<b>69.4%</b>	<b>68.6%</b>	<b>69.6%</b>	<b>69.9%</b>	<b>70.2%</b>	<b>69.6%</b>	<b>71.0%</b>
+ Amortization of acquired intangible assets	0.2%	0.2%	0.2%	-0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
+ Stock-based compensation	0.3%	0.4%	1.0%	1.4%	0.8%	1.8%	0.3%	0.2%	0.2%	0.6%	0.5%
+ Purchase accounting adjustments on acquisitions	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Non-GAAP Gross Margin</b>	<b>70.9%</b>	<b>71.2%</b>	<b>69.3%</b>	<b>69.7%</b>	<b>70.2%</b>	<b>70.4%</b>	<b>69.9%</b>	<b>70.1%</b>	<b>70.5%</b>	<b>70.2%</b>	<b>71.6%</b>

NON-GAAP OPERATING EXPENSES	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
<b>Research &amp; Development, GAAP</b>	\$ 18,012	\$ 19,105	\$ 20,357	\$ 23,244	\$ 80,718	\$ 16,582	\$ 18,276	\$ 18,679	\$ 22,281	\$ 76,268	\$ 17,560
- Stock-based compensation in R&D	4,315	5,614	7,207	9,894	27,030	3,644	4,159	3,307	8,421	19,531	4,001
<b>Non-GAAP R&amp;D</b>	<b>13,697</b>	<b>13,491</b>	<b>13,150</b>	<b>13,350</b>	<b>53,688</b>	<b>12,938</b>	<b>14,117</b>	<b>15,372</b>	<b>13,860</b>	<b>56,737</b>	<b>13,559</b>
<b>Sales General &amp; Administrative, GAAP</b>	<b>113,727</b>	<b>112,731</b>	<b>109,200</b>	<b>114,541</b>	<b>450,199</b>	<b>127,017</b>	<b>118,507</b>	<b>124,303</b>	<b>128,699</b>	<b>498,526</b>	<b>137,057</b>
- Stock-based compensation in SG&A	12,524	10,792	8,816	9,154	41,286	15,631	10,912	12,658	10,458	49,659	18,688
- Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-
<b>Non-GAAP SG&amp;A</b>	<b>101,203</b>	<b>100,331</b>	<b>100,384</b>	<b>105,387</b>	<b>407,305</b>	<b>111,386</b>	<b>107,595</b>	<b>111,645</b>	<b>118,241</b>	<b>448,867</b>	<b>118,369</b>
<b>Other Operating Expense, GAAP</b>	<b>8,953</b>	<b>6,065</b>	<b>6,875</b>	<b>7,621</b>	<b>29,514</b>	<b>16,688</b>	<b>5,403</b>	<b>10,251</b>	<b>7,330</b>	<b>39,222</b>	<b>4,440</b>
- Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
- Amortization of acquired intangibles assets	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915
- Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
- Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
<b>Non-GAAP Other Operating Expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total Non-GAAP Operating Expenses</b>	<b>\$ 114,900</b>	<b>\$ 113,822</b>	<b>\$ 113,534</b>	<b>\$ 118,737</b>	<b>\$ 460,993</b>	<b>\$ 124,324</b>	<b>\$ 121,712</b>	<b>\$ 127,017</b>	<b>\$ 132,101</b>	<b>\$ 505,604</b>	<b>\$ 131,928</b>
<b>Non-GAAP Operating Expenses as a % of Revenue</b>											
Research & development	9.9%	9.3%	8.7%	7.6%	8.8%	7.6%	7.6%	7.8%	6.5%	7.4%	7.1%
Sales, general & administrative	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%	61.6%
<b>Total Non-GAAP Operating Expenses as a % of Revenue</b>	<b>83.0%</b>	<b>78.2%</b>	<b>75.3%</b>	<b>67.2%</b>	<b>75.4%</b>	<b>73.5%</b>	<b>65.6%</b>	<b>64.6%</b>	<b>62.0%</b>	<b>66.2%</b>	<b>68.7%</b>

# SUPPLEMENTAL FINANCIAL INFORMATION



## NON-GAAP RECONCILIATION - CONSOLIDATED (\$'000's)

ADJUSTED EBITDA	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Net loss, GAAP	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)	\$ (33,906)
Cash interest expense, net	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953
Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768
Loss on debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-
Gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-
Other (expense) income, net	(118)	(156)	(623)	1,922	1,025	(337)	(993)	(307)	34	(1,603)	(446)
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50
Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629
Amortization expense	4,161	4,143	4,156	3,906	16,366	4,153	4,316	4,267	4,406	17,142	4,506
<b>Total EBITDA</b>	<b>(25,456)</b>	<b>(15,429)</b>	<b>(13,056)</b>	<b>(3,810)</b>	<b>(57,751)</b>	<b>(24,384)</b>	<b>6,243</b>	<b>3,223</b>	<b>10,282</b>	<b>(4,636)</b>	<b>(3,446)</b>
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
+ Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-
<b>Total Adjusted EBITDA</b>	<b>\$ (3,035)</b>	<b>\$ 5,565</b>	<b>\$ 7,433</b>	<b>\$ 20,624</b>	<b>\$ 30,587</b>	<b>\$ 10,519</b>	<b>\$ 23,467</b>	<b>\$ 26,122</b>	<b>\$ 33,137</b>	<b>\$ 93,245</b>	<b>\$ 20,738</b>
<i>Adjusted EBITDA as a % of Revenue</i>	<i>-2.2%</i>	<i>3.8%</i>	<i>4.9%</i>	<i>11.7%</i>	<i>5.0%</i>	<i>6.2%</i>	<i>12.6%</i>	<i>13.3%</i>	<i>15.6%</i>	<i>12.2%</i>	<i>10.8%</i>

NON-GAAP EARNINGS (LOSS) PER SHARE	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Net Loss, GAAP	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)	\$ (33,906)
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659
+ Amortization of acquired intangible assets	4,161	4,143	4,156	3,906	16,366	4,153	3,867	3,796	3,939	15,305	3,981
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
+ Loss on Debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-
+ Gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-
+ Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768
+ Foreign exchange impact	(119)	(44)	(624)	1,592	805	(312)	(308)	(29)	(60)	(708)	(429)
+ Long-term income tax rate adjustment	5,448	4,606	3,800	21	13,875	2,811	(848)	(1,563)	(3,283)	(2,766)	(218)
<b>Non-GAAP net income (loss)</b>	<b>\$ (15,526)</b>	<b>\$ (11,725)</b>	<b>\$ (10,640)</b>	<b>\$ (2,195)</b>	<b>\$ (40,086)</b>	<b>\$ (7,691)</b>	<b>\$ 2,591</b>	<b>\$ 4,091</b>	<b>\$ 9,432</b>	<b>\$ 8,091</b>	<b>\$ 380</b>
Non-GAAP net income (loss) per share	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02	\$ 0.03	\$ 0.06	\$ 0.05	\$ 0.00
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051

# SUPPLEMENTAL FINANCIAL INFORMATION



## NON-GAAP P&L TREND - CONSOLIDATED (\$000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Revenue from products and services	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155	\$ 192,108
Non-GAAP cost of sales	40,336	41,921	46,243	53,534	182,034	50,091	55,826	58,724	62,852	227,493	54,596
<b>Non-GAAP gross profit</b>	<b>\$ 98,141</b>	<b>\$ 103,652</b>	<b>\$ 104,476</b>	<b>\$ 123,259</b>	<b>\$ 429,528</b>	<b>\$ 119,089</b>	<b>\$ 129,718</b>	<b>\$ 137,779</b>	<b>\$ 150,076</b>	<b>\$ 536,662</b>	<b>\$ 137,512</b>
<i>Non-GAAP Gross Margin</i>	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%	71.6%
<b>Non-GAAP Operating expenses:</b>											
Non-GAAP research & development	13,697	13,491	13,150	13,350	53,688	12,938	14,117	15,372	13,860	56,737	13,559
Non-GAAP sales, general & administrative	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867	118,369
<b>Total non-GAAP operating expenses</b>	<b>\$ 114,900</b>	<b>\$ 113,822</b>	<b>\$ 113,534</b>	<b>\$ 118,737</b>	<b>\$ 460,993</b>	<b>\$ 124,324</b>	<b>\$ 121,712</b>	<b>\$ 127,017</b>	<b>\$ 132,101</b>	<b>\$ 505,604</b>	<b>\$ 131,928</b>
<i>Non-GAAP R&amp;D as % of revenue</i>	9.9%	9.3%	8.7%	7.6%	8.8%	7.6%	7.6%	7.8%	6.5%	7.4%	7.1%
<i>Non-GAAP SG&amp;A as % of revenue</i>	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%	61.6%
<i>Total Non-GAAP OPEX as % of revenue</i>	83.0%	78.2%	75.3%	67.2%	75.4%	73.5%	65.6%	64.6%	62.0%	66.2%	68.7%
<b>Non-GAAP operating income (loss)</b>	<b>(16,759)</b>	<b>(10,170)</b>	<b>(9,058)</b>	<b>4,522</b>	<b>(31,465)</b>	<b>(5,235)</b>	<b>8,006</b>	<b>10,762</b>	<b>17,975</b>	<b>31,058</b>	<b>5,584</b>
<i>Op income (loss) as % of revenue</i>	-12.1%	-7.0%	-6.0%	2.6%	-5.1%	-3.1%	4.3%	5.5%	8.4%	4.1%	2.9%
<i>Cash interest expense</i>	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953
<i>Other income</i>	1	1,693	1	330	2,025	(25)	(685)	(278)	94	(895)	(17)
<i>Long-term income tax rate adjustment</i>	(5,517)	(4,892)	(3,836)	420	(13,825)	(2,875)	811	1,637	3,265	2,721	268
<b>Non-GAAP net income (loss)</b>	<b>(15,526)</b>	<b>(11,725)</b>	<b>(10,640)</b>	<b>(2,195)</b>	<b>(40,086)</b>	<b>(7,691)</b>	<b>2,591</b>	<b>4,091</b>	<b>9,432</b>	<b>8,091</b>	<b>380</b>
Non-GAAP net income (loss) per share	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02	\$ 0.03	\$ 0.06	\$ 0.05	\$ 0.00
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051
<b>Non-GAAP operating income (loss)</b>	<b>(16,759)</b>	<b>(10,170)</b>	<b>(9,058)</b>	<b>4,522</b>	<b>(31,465)</b>	<b>(5,235)</b>	<b>8,006</b>	<b>10,762</b>	<b>17,975</b>	<b>31,058</b>	<b>5,584</b>
Less: Other amortization expense	-	-	-	-	-	-	449	471	467	1,837.00	525
Less: Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629
<b>Adjusted EBITDA</b>	<b>\$ (3,035)</b>	<b>\$ 5,565</b>	<b>\$ 7,433</b>	<b>\$ 20,624</b>	<b>\$ 30,587</b>	<b>\$ 10,519</b>	<b>\$ 23,467</b>	<b>\$ 26,122</b>	<b>\$ 33,137</b>	<b>\$ 93,245</b>	<b>\$ 20,738</b>
<i>Adj EBITDA as % of revenue</i>	-2.2%	3.8%	4.9%	11.7%	5.0%	6.2%	12.6%	13.3%	15.6%	12.2%	10.8%
<i>Adj EBITDA drop through %</i>	14.5%	30.4%	24.2%	48.8%	30.7%	44.1%	44.8%	40.8%	34.6%	41.1%	44.6%

# SUPPLEMENTAL FINANCIAL INFORMATION



## REVENUE SUPPLEMENT

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
<b>Revenues:</b>											
Products and services - Surgical	122,617	130,028	135,343	156,468	544,456	152,084	168,217	176,676	189,769	686,746	178,124
Products and services - EOS	15,860	15,545	15,376	20,325	67,106	17,096	17,327	19,827	23,159	77,409	13,984
<b>Total revenue from products and services</b>	<b>\$ 138,477</b>	<b>\$ 145,573</b>	<b>\$ 150,719</b>	<b>\$ 176,793</b>	<b>\$ 611,562</b>	<b>\$ 169,180</b>	<b>\$ 185,544</b>	<b>\$ 196,503</b>	<b>\$ 212,928</b>	<b>\$ 764,155</b>	<b>\$ 192,108</b>
<b>Constant currency adjustments:</b>											
Products and services - Surgical	67	18	(13)	(72)	-	180	80	75	93	428	(387)
Products and services - EOS	(88)	42	27	(146)	(165)	405	(167)	(435)	(589)	(786)	(727)
Revenue from products and services	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)	(1,114)
<b>TOTAL ADJUSTMENTS</b>	<b>(21)</b>	<b>60</b>	<b>14</b>	<b>(218)</b>	<b>(165)</b>	<b>585</b>	<b>(87)</b>	<b>(360)</b>	<b>(496)</b>	<b>(358)</b>	<b>(1,114)</b>
<b>Revenues at constant currency:</b>											
Products and services - Surgical	122,684	130,046	135,330	156,396	544,456	152,264	168,297	176,751	189,862	687,174	177,737
Products and services - EOS	15,772	15,586	15,403	20,179	66,940	17,501	17,160	19,392	22,570	76,623	13,257
<b>Total Revenue at Constant Currency</b>	<b>\$ 138,456</b>	<b>\$ 145,632</b>	<b>\$ 150,733</b>	<b>\$ 176,575</b>	<b>\$ 611,396</b>	<b>\$ 169,765</b>	<b>\$ 185,457</b>	<b>\$ 196,143</b>	<b>\$ 212,432</b>	<b>\$ 763,797</b>	<b>\$ 190,994</b>

<b>YOY GROWTH %</b>	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%
Products and services - EOS	5%	6%	6%	32%	13%	8%	11%	29%	14%	15%	-18%
<b>Total revenue from products and services</b>	<b>27%</b>	<b>25%</b>	<b>27%</b>	<b>28%</b>	<b>27%</b>	<b>22%</b>	<b>27%</b>	<b>30%</b>	<b>20%</b>	<b>25%</b>	<b>14%</b>
<b>YOY growth % at constant currency:</b>											
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%
Products and services - EOS	2%	7%	9%	34%	13%	11%	10%	26%	12%	14%	-24%
<b>Total Revenue Growth % at Constant Currency</b>	<b>26%</b>	<b>25%</b>	<b>28%</b>	<b>28%</b>	<b>27%</b>	<b>23%</b>	<b>27%</b>	<b>30%</b>	<b>20%</b>	<b>25%</b>	<b>13%</b>